Constipation is a condition in which there is a reduction in stool frequency up to 3x per week having difficulty for stool passing. The chronic constipation is a frequent functional gastrointestinal condition that adversely affects the patient’s life. The chronic idiopathic constipation is descried as presence chronic constipation symptoms with zero underlying well-defined cause. Chronic idiopathic constipation symptoms include bowel movements that are infrequent, hard stools, feeling of an incomplete evacuation, straining while defecation, bloating sensation, and abdominal discomfort. The chronic idiopathic constipation is detected by endoscopy, laboratory tests, radiological tests, physiological testing, and magnetic resonance imaging. Presently, very limited approved options of treatment are available of chronic idiopathic constipation that is a key factor expected to restrain the global chronic idiopathic constipation treatment market growth over the forecast period. However, this provides opportunity for market players to develop novel treatments for gaining the dominant position in the global chronic idiopathic constipation treatment market.
Request for Analysis of COVID-19 Impact on Chronic Idiopathic Constipation (CIC) Treatment Market –
Increasing drug approvals and clinical trials by pharmaceutical players for fulfilling unmet medical requirements for the treatment of chronic idiopathic constipation is expected to drive growth of the global chronic idiopathic constipation treatment market over the forecast period. For instance, Shire plc, in March 2018, received latest drug applications by the U.S. Food and Drug Administration (FDA) for drug candidate, SHP555 (prucalopride) to indicate chronic idiopathic constipation within adults.
Furthermore, SHP555 (prucalopride), in 2015, received the European Commission approval for symptomatic treatments of the chronic constipation within adults with laxative treatment failure. Furthermore, the Renexxion is performing clinical trial of phase 2 of Naronapride (ATI-7505) to treat various gastrointestinal disorders, including chronic idiopathic constipation. The U.S. FDA, in 2017, approved Linzess (linaclotide) by Allergan and Ironwood to treat chronic idiopathic constipation. However, half of the patients having chronic constipation are not satisfied with the current treatment, majorly due to lack of efficiency, highlighting a continuous medical requirement for more safer and effective therapeutic agents.
However, usage of alternate therapies including herbal medication and home-based remedies including probiotic foods, herbal laxative, etc. are major factors expected to hinder growth of the global chronic idiopathic constipation treatment market over the forecast period.
Request PDF Brochure Report –
Global Chronic Idiopathic Constipation (CIC) Treatment Market – Regional Analysis
Based on region the global chronic idiopathic constipation treatment market was segmented into North America, Europe, Latin America, Asia Pacific, Africa, and Middle East. North America holds the largest share in the global chronic idiopathic constipation treatment market due to high rate of population affected by chronic constipation. For instance, as per the European Journal of Pharmacology, in the U.S., 2017, over 12%–19% populace is affected by chronic constipation. It is expected to drive the global chronic idiopathic constipation treatment market growth in the region during the forecast period. Asia Pacific is expected to register robust growth, due to high prevalence rate of constipation within the Asian regions. As per the 2016 article by the Journal of Neurogastroenterology and Motility, prevalence rate of constipation ranges reportedly from 8.2% till 16.8% in countries including China, Hong Kong, India, and Korea, which is expected to drive the global chronic idiopathic constipation treatment market growth in the region during the forecast period.
Global Chronic Idiopathic Constipation (CIC) Treatment Market – Competitive Analysis
Major players functioning in the global chronic idiopathic constipation treatment market include Ironwood Pharmaceuticals, Synergy Pharmaceuticals, Inc., Allergan, Shire plc, Mallinckrodt plc, and others. Presence of limited market players offers wide opportunities for new entrants in the global chronic idiopathic constipation market. Furthermore, Mallinckrodt plc, a pharmaceutical company of global specialty, in February 2018, acquired the biopharmaceutical company- Sucampo Pharmaceuticals, Inc. Assets of this acquisition includes blockbuster drug approved by the U.S. FDA – Amitiza (lubiprostone) to treat chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C) in adults. Sucampo Pharmaceuticals, Inc. even partnered with Dr. Reddy’s Laboratories Ltd. and Par Pharmaceuticals, Inc. in this agreement, where both partners were given the non-exclusive license for marketing lubiprostone’s generic version by Par, from January, 2021, in the U.S. These inorganic strategies by market players is expected to drive the global chronic idiopathic constipation treatment market growth over the forecast period. Ferring Pharmaceuticals, in 2012, acquired rights to develop and commercialize Elobixibat, the first-in-class compound for the chronic idiopathic constipation by Albireo AB, a Sweden-based biotechnology company. Furthermore, Ferring Pharmaceuticals, in 2013, initiated clinical trials of phase III for Elobixibat.
Reasons to Purchase this Report
Current and future of global Chronic Idiopathic Constipation (CIC) Treatment market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Buy This Complete A Business Report With Flat US $2000 Off @
Global Chronic Idiopathic Constipation (CIC) Treatment Market Taxonomy
Based on drug, Based on
Based on distribution channel,
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Based on geography,
- North America
- Latin America
- Asia Pacific
- Middle East
Major Point Answered in Chronic Idiopathic Constipation (CIC) Treatment Market Research Study are:
What will be the progress rate of the Chronic Idiopathic Constipation (CIC) Treatment Market for the conjecture period, 2020-2027?
What are the prominent factors driving the Chronic Idiopathic Constipation (CIC) Treatment Market across different regions?
Who are the major vendors dominating the Chronic Idiopathic Constipation (CIC) Treatment industry and what are their winning strategies?
What will be the market scope for the estimated period?
What are the major trends shaping the expansion of the industry in the coming years?
What are the challenges faced by the Chronic Idiopathic Constipation (CIC) Treatment Market?
Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027